Clinical Trial Update: Open Label Extension Study of [S,S]-Reboxetine in Patients With Fibromyalgia [Phase 3]

View source ↗

Summary

Open-label extension study update for S,S-Reboxetine in fibromyalgia (Phase 3) terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fibromyalgia

Drugs mentioned

• S,S-Reboxetine (reboxetine)

Snippet

Sponsor: Pfizer | Conditions: Fibromyalgia | Phase 3 | Status: TERMINATED